The quarter split cleanly: earnings beat, but revenue missed. Diluted EPS of $7.27 exceeded the published consensus of roughly $6.86, while revenue of $783.3 million fell short of the roughly $807 million expected. That is not an across-the-board beat: the market got better per-share profit but a weaker-than-expected top line. (Financial Highlights)
| Metric | Q2 2026 | Q2 2025 | Published expectation | Read |
|---|---|---|---|---|
| Revenue | $783.3M | $798.6M | ~$807M | ~$23.7M below expectation; down 2% YoY (Financial Highlights) |
| Diluted EPS | $7.27 | $6.41 | ~$6.86 | ~$0.41 above expectation; up 13% YoY (Consolidated Statements of Operations) |
| Operating income | $330.8M | $364.5M | — | Down 9% YoY (Consolidated Statements of Operations) |
| Total Tyvaso revenue | $452.6M | $469.6M | — | Down 4% YoY (Revenue by product) |
| Tyvaso DPI revenue | $326.6M | $315.2M | — | Up 4% YoY, but growth slowed from Q1's 9% pace (Revenue by product) |
| Effective tax rate | 11% | 24% | — | Major support for net income growth (Income tax expense) |
The EPS upside was helped more by below-the-line items and buybacks than by operating momentum. Operating income declined $33.7 million year over year as revenue fell and operating expenses rose. Net income still increased because tax expense dropped to $39.7 million from $98.9 million, producing an 11% effective tax rate, while the accelerated repurchase reduced diluted shares to 45.8 million from 48.3 million. Those factors make the EPS beat real, but less indicative of improving underlying demand. (Consolidated Statements of Operations; Income tax expense; Share repurchase)
Tyvaso's mix is improving, but the franchise is still shrinking. Tyvaso DPI added $11.4 million, yet Nebulized Tyvaso lost $28.4 million, leaving total Tyvaso down $17.0 million. Management explicitly attributes pressure across Nebulized Tyvaso, DPI, and Remodulin to competing therapies; that is the key commercial issue behind the revenue miss. DPI is offsetting erosion rather than yet restoring franchise growth. (Revenue by product; Total Tyvaso revenues discussion)
The regulatory filings add a concrete long-term catalyst, not an immediate commercial fix. The company says it submitted applications for ralinepag tablets in PAH and Nebulized Tyvaso in IPF, potentially expanding the addressable market if approved. But the filing supplies no approval decision, launch timing, or revenue contribution; against the current quarter's revenue shortfall, these are future opportunities rather than a change in present operating performance. (Forward-Looking Statements; CEO commentary)
Net read: mixed rather than positive. The earnings beat repairs some of the damage from the prior quarter's EPS miss, but it came alongside a revenue miss, falling operating income, and continuing pressure in the core Tyvaso franchise. The filing improves the per-share outcome, not yet the near-term growth picture.
Read the original 8-K on SEC EDGAR ↗